4-苄氧基-1-BOC-吲哚-2-硼酸 | 850568-52-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-苄氧基-1-BOC-吲哚-2-硼酸
• 中文别名: 4-(苄氧基)-1-(叔丁氧羰基)-1H-吲哚-2-基硼酸；1H-吲哚-1-甲酸,2-硼酸基-4-(苯基甲氧基)-,1-(1,1-二甲基乙基)酯；4-苄氧基-1-Boc-吲哚-2-硼酸
• 英文名称: (4-(benzyloxy)-1-(tert-butoxycarbonyl)-1H-indol-2-yl)boronic acid
• 英文别名: [4-(benzyloxy)-1-(tert-butoxycarbonyl)-1H-indol-2-yl]boronic acid；4-(benzyloxy)-1-(tert-butoxycarbonyl)-1H-indol-2-ylboronic acid；(1-tert-butoxycarbonyl-4-benzyloxy-indol-2-yl)-boronic acid；[1-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenylmethoxyindol-2-yl]boronic acid
• CAS: 850568-52-4
• 化学式: C₂₀H₂₂BNO₅
• 分子量: 367.209
• InChiKey: YXJBIADEQVCONT-UHFFFAOYSA-N

物化性质

• 熔点：
  102-104
• 沸点：
  564.7±60.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.68
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Benzyloxy-1-BOC-indole-2-boronic acid
Synonyms: 4-Benzyloxy-1-t-butoxycarbonylindole-2-boronic acid; 4-Benzyloxy-1-BOC-2-indoleboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H317: May cause an allergic skin reaction
H319: Causes serious eye irritation
H413: May cause long lasting harmful effects to aquatic life
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Benzyloxy-1-BOC-indole-2-boronic acid
CAS number: 850568-52-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C20H22BNO5
Molecular weight: 367.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-碘吡啶 、 4-苄氧基-1-BOC-吲哚-2-硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 碳酸氢钠 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.25h， 生成
  参考文献：
  名称：

  [EN] RENIN INHIBITORS
  [FR] INHIBITEURS DE LA RÉNINE

  摘要：

  公开号：

  WO2010111634A3

文献信息

• Discovery and structure–activity relationship studies of indole derivatives as liver X receptor (LXR) agonists
  作者：Farid Bakir、Sunil Kher、Madhavi Pannala、Norma Wilson、Trang Nguyen、Ila Sircar、Kei Takedomi、Chiaki Fukushima、James Zapf、Kui Xu、Shao-Hui Zhang、Juping Liu、Lisa Morera、Lisa Schneider、Naoki Sakurai、Rick Jack、Jie-Fei Cheng

  DOI：10.1016/j.bmcl.2007.03.076

  日期：2007.6

  A structurally novel liver X receptor (LXR) agonist (1) was identified from internal compound collection utilizing the combination of structure-based virtual screening and high-throughput gene profiling. Compound 1 increased ABCA1 gene expression by eightfold and SREBP1c by threefold in differentiated THP-1 macrophage cell lines. Confirmation of its agonistic activity against LXR was obtained in the

  利用基于结构的虚拟筛选和高通量基因分析相结合的方法，从内部化合物收集中鉴定出一种结构新颖的肝X受体（LXR）激动剂（1）。在分化的THP-1巨噬细胞系中，化合物1使ABCA1基因表达增加了8倍，而SREBP1c增加了3倍。在辅助因子募集和报告基因反式激活测定中获得了其对LXR的激动活性的证实。描述了对化合物1的构效关系研究。
• Novel Bicyclic Pyridinones
  申请人：Pfizer Inc.

  公开号：US20140045790A1

  公开（公告）日：2014-02-13

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本文披露了化合物及其医药上可接受的盐，其中所述化合物具有如下所定义的I式结构。同时还披露了相应的药物组合物、治疗方法、合成方法和中间体。
• Bicyclic pyridinones
  申请人：Pfizer Inc.

  公开号：US09067934B2

  公开（公告）日：2015-06-30

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本文披露了化合物及其医药上可接受的盐，其中化合物的结构符合此处定义的公式I。同时还披露了相应的制药组合物、治疗方法、合成方法和中间体。
• WO2008/11521
  申请人：——

  公开号：——

  公开（公告）日：——
• WO2007/147874
  申请人：——

  公开号：——

  公开（公告）日：——